Seeks businesses to merge with and give access to U.S. public markets, with a proposed combination involving Vesicor Therapeutics.
10-K for FY2025, filed Mar 6, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 6, 2026
10-Q for Q3 FY2026, filed Oct 6, 2026
$1.1MView ↗
8-K, filed Apr 1, 2026
On March 31, 2026, Black Hawk Acquisition Corporation (the “Company”) received a notice (the “MVLS Notice”) from the Listing Qualifications…View ↗
Loading...